Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 2

August 04, 2022 by Suzanne Mahon RN, DNSc, AOCN®, AGN-BC

Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant disease that occurs because of germline pathogenic variants in the rearranged during transfection (RET) proto-oncogene. The RET gene was isolated in 1993 and pathogenic variants affect 1–10 per 100,000 people. Approximately 50% of cases are de novo.

Cancer Risk by Phenotype

MEN2 includes three phenotypes: MEN2A, the familial medullary thyroid carcinoma (FMTC) variant of MEN2A, and MEN2B. All three phenotypes increase a patient’s risk for developing medullary carcinoma of the thyroid (MTC); MEN2A and MEN2B also increase the risk for pheochromocytoma and parathyroid tumors (see sidebar). MEN2B’s other clinical features include distinctive facial features (i.e., lips becoming more prominent as a child grows), mucosal neuromas, and ganglioneuromatosis of the gastrointestinal tract. The phenotype depends on the specific pathogenic variant.

Although MTC accounts for only 5% of all thyroid cancer cases, it is responsible for 15% of all thyroid cancer deaths. MTC is aggressive and associated with an increased risk of metastasis to the lungs, liver, and bones. About 25%–30% of all individuals with MTC have a germline RET pathogenic variant. Because of their increased risk for morbidity and mortality, all patients with MTC should be offered testing for pathogenic RET variants. Those who test positive should be educated about risk-reducing thyroidectomy and other intensive screening as well as cascade testing for other family members so they can clarify their individual risk and engage in prevention and early detection measures.


Because of the significant morbidity and mortality associated with MTC, pheochromocytoma, and parathyroid disease, prevention is the best management strategy for MEN2.

Prophylactic thyroidectomy is recommended for individuals with an identified germline RET pathogenic variant. Depending on the specific pathogenic variant, this can be recommended for patients as young as 6 months to 1 year. Infants from families with a known pathogenic variant should be tested at birth.

Prior to surgery, patients with MEN2A or MEN2B should obtain biochemical screening, including measurement of catecholamine and metanephrine levels, to exclude a functioning pheochromocytoma. Similarly, females with MEN2 should be screened for pheochromocytoma prior to planned pregnancies or as early as possible during unplanned pregnancies to reduce complications from a hypertensive crisis. Dopamine D2 receptor antagonists and beta-adrenergic receptor antagonists are contraindicated in patients with MEN2 and pheochromocytoma because of a high risk for adverse reactions.

Early Detection

Patients with MEN2 should also have regular surveillance, including:

Nursing Implications

Management of MEN2 requires ongoing lifetime screening beginning in infancy. Families need psychosocial support and a consistent team of providers to implement prevention and detection measures.

Individuals should be educated about the following symptoms to report and evaluate promptly:

Recognizing MEN2 syndromes and referring all individuals with MTC for genetic assessment allow patients and providers to initiate screening and preventive surgery, which significantly reduces associated morbidity and mortality.

Genetic Disorder Reference Sheet:  Multiple Endocrine Neoplasia Type 2

Copyright © 2022 by the Oncology Nursing Society. User has permission to print one copy for personal or unit-based educational use. Contact for quantity reprints.